Niapelf (Paliperidone)

Paliperidone is an atypical antipsychotic used in the management of psychotic disorders.

• Schizophrenia: reduces positive and negative symptoms and helps maintain stability.
• Schizoaffective disorder: controls both mood and psychotic features.
• Maintenance therapy for schizophrenia: prevents relapse and reduces hospitalization risk.

• Paliperidone exerts its antipsychotic effect primarily by antagonizing dopamine D2 receptors and serotonin 5‑HT2A receptors in the central nervous system. This dual blockade modulates dopaminergic and serotonergic neurotransmission, leading to decreased psychotic symptomatology and mood stabilization without significant cholinergic activity.

Paliperidone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Weight gain: increase in body weight over treatment duration.
• Akathisia: restlessness or an inability to stay still.
• Somnolence: feeling unusually sleepy or fatigued.
• Elevated prolactin: menstrual disturbances or galactorrhea.
• Dizziness: transient light‑headedness, especially on standing.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: life‑threatening reaction with fever, rigidity, and autonomic instability.
• Tardive dyskinesia: persistent involuntary movements, often of the face or tongue.
• Seizures: increased risk in susceptible individuals.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Agranulocytosis: dangerously low white‑blood‑cell count.

Before initiating therapy with Paliperidone, clinicians should consider several safety aspects.

• Metabolic monitoring: regularly assess weight, glucose, and lipid levels.
• Cardiovascular assessment: evaluate for history of arrhythmia or orthostatic hypotension.
• Seizure risk: avoid in patients with uncontrolled epilepsy.
• Prolactin effects: monitor for galactorrhea, menstrual changes, or sexual dysfunction.
• Elderly patients with dementia: use with caution due to increased mortality risk.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Paliperidone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase paliperidone plasma levels.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise exposure and risk of adverse effects.
• Other dopamine antagonists (e.g., haloperidol): additive risk of extrapyramidal symptoms.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents: may enhance orthostatic hypotension.

• CNS depressants (e.g., benzodiazepines, opioids): increase sedation and dizziness.